-
A Look At All Of Pfizer's Acquisitions Over The Past 2 Years
Tuesday, May 17, 2016 - 11:22am | 501Read More...Pfizer Inc. (NYSE: PFE) is back on the M&A hunt, having agreed to acquire Anacor Pharmaceuticals Inc (NYSE: ANAC) for $5.2 billion. Ironically, it is nearly two years to the day from when AstraZeneca plc (ADR) (NYSE: AZN) rejected Pfizer's final offer to acquire the company for £...
-
Pfizer Receives FDA Approval For Cheaper Version Of Johnson & Johnson's Top Drug Remicade
Wednesday, April 6, 2016 - 10:45am | 327Read More...Pfizer Inc. (NYSE: PFE) announced after Tuesday's market close that the U.S. Food and Drug Administration approved INFLECTRA, the first and only biosimilar monoclonal antibody therapy, and only the second biosimilar to be approved in the US. INFLECTRA is a treatment indicated for reducing...
-
Pfizer Reports Better-Than-Expected Q4, Shares Dip Lower
Tuesday, February 2, 2016 - 8:23am | 229Read More...Shares of Pfizer Inc. (NYSE: PFE) were trading lower by around 0.5 percent early Tuesday morning after the company reported its fourth quarter results. Pfizer earned $0.53 per share in the fourth quarter on revenue of $14.05 billion. Wall Street analysts were expecting the company to earn $0.52...
-
Why M&A Doesn't Make Sense For Pfizer Anytime Soon
Thursday, August 13, 2015 - 8:28am | 369Read More...In a report published Wednesday, Bank of America analyst Colin Bristow detailed an investor meeting held with Pfizer Inc. (NYSE: PFE)'s CEO Ian Read and other key senior executives. According to Bristow's meeting, Pfizer noted that one (or several) transformative M&A deal is "...
-
Mizuho Analyst On The Fence At Medicines Co. Pending Patent Appeal
Saturday, April 11, 2015 - 12:49pm | 272Read More...Uncertainty over patents on The Medicines Company (NASDAQ: MDCO)'s lead blood-clot drug Angiomax will hurt results going forward, an analyst said Friday. Hospira, Inc. (NYSE: HSP) is set to launch a generic version of Angiomax in June under a court ruling concerning a patent dispute last...
-
Fresenius SE, Permira Interested In Acquiring Danone's Medical Unit
Wednesday, November 19, 2014 - 4:13pm | 225Read More...German based health care group Fresenius SE and European buyout firm Permira have made a joint bid to acquire Danone's (OTC: DANOY) medical nutrition business for as much as 4.5 billion euro. The Wall Street Journal reported Wednesday afternoon that Danone will entertain other offers...
-
Wedbush Initiates Coverage On Cubist Pharmaceuticals
Tuesday, November 4, 2014 - 12:09pm | 234Read More...Wedbush initiated coverage on Cubist Pharmaceuticals Inc (NASDAQ: CBST) with a Neutral rating and $70 price target. Analysts led by Heather Behanna commented that "Cubist is in transition from a one-product company to a leader in the antibiotic arena. Cubist has three antibiotic products...
-
#PreMarket Primer: Monday, July 28: Tension Between U.S. And Israel On The Rise
Monday, July 28, 2014 - 6:59am | 1184Read More...With the fighting between Israeli forces and Hamas militants temporarily on hold due to a 24 hour pledge to stop the fighting, many are criticizing U.S. Secretary for State John Kerry for being too accommodative of Hamas in the truce agreement. On Monday, Israeli officials said the nation doesn...
-
Market Wrap For April 1: S&P 500 Hitting New All-Time High Not An April Fools' Joke
Tuesday, April 1, 2014 - 4:47pm | 1704Read More...U.S. stocks kicked off a new month and new quarter with solid gains as U.S. manufacturing growth improved in March. The indexes have now logged a three-day winning streak, an accomplishment which was completely absent throughout all of March. The S&P 500 hit new all-time highs of 1,885.84...
-
Top Trending Tickers On StockTwits For February 12
Wednesday, February 12, 2014 - 9:52am | 823Read More...Here's a look at the top tickers trending on StockTwits.com TripAdvisor: In-line quarter Last night, TripAdvisor (NASDAQ: TRIP) reported its fourth quarter earnings. The company announced an EPS of $0.21, in-line with the consensus estimate. Revenue of $212.7 million beat the consensus of $205....
-
Barron's Recap (2/9/12): Best Fund Families
Saturday, February 9, 2013 - 4:05pm | 917Read More...This weekend in Barron's online: the annual Barron's/Lipper Fund Family Ranking, why the Dell buyout deal may unravel, and the prospects for CSX, Hospira, and Wendy's. Cover Story "All in the Family" by Lawrence C. Strauss. It is time again for the Barron's/Lipper Fund Family Ranking, and the...
-
Caterpillar, Discover Financial and Other Illinois Primary Stock Picks
Tuesday, March 20, 2012 - 6:42am | 1149Read More...Today, Illinois holds its Republican Primary, as the candidates hope to add to their delegate counts. Polls show a close race between frontrunners Mitt Romney and Rick Santorum. While the focus is on Illinois, let's have a look at the stocks of some of the many corporations headquartered in the...
-
Goldman Sachs Maintains Neutral on Hospira
Tuesday, July 12, 2011 - 8:25am | 152Read More...Goldman Sachs is out with its report today on Hospira (NYSE: HSP), maintaining Neutral. In a note to clients, Goldman Sachs writes, "Shifting to the long term, we think the company needs to bridge the gap between the slowing sales from Paragraph IV challenge drugs (2012) and the eventual impact...
-
Citi Maintains Sell Rating on Hospira
Tuesday, July 5, 2011 - 8:58am | 70Read More...Citi is maintaining its Sell rating on shares of Hospira (NYSE: HSP). “We maintain our Sell rating, as we remain cautious on increasing competitive pressures along with downside risk to 2012 consensus EPS,” Citi writes. “We leave our 2011 $4.04 EPS estimate unchanged though we lower 2H (offset by...
-
Morgan Stanley Reiterates Equal-Weight on Hospira
Tuesday, July 5, 2011 - 7:39am | 45Read More...Morgan Stanley reiterated its Equal-Weight rating on Hospira (NYSE: HSP). At the moment, Morgan Stanley does not have a price target on the company's stock. On Friday, Hospira lost 1.75% of its value to end the week at $55.67.
